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Abstract
Background Cardiovascular disease is the leading cause
of morbidity and mortality in patients with kidney failure.
Nocturnal home hemodialysis (NHD) is a form of kidney
replacement therapy whereby hemodialysis is performed
for at least 6-h overnight, at least 4 days per week. Little is
known about the effects of NHD on cardiovascular
remodeling as assessed by transthoracic echocardiography
(TTE) and cardiac magnetic resonance imaging (CMR).
Objectives The primary objective of the study was to
determine the long-term effects of NHD on cardiovascular
remodeling using different imaging modalities over a one-
year follow-up.
Methods and results A total of 11 patients were included
in the study (6 males, mean age 48 ± 16 years) between
2009 and 2011 inclusive at a single tertiary care center. All
patients underwent TTE and CMR at baseline and after
1 year of NHD. Left ventricular mass index decreased
significantly at 1 year by both TTE (152 ± 7–129 ± 8 g/
m2, p\ 0.05) and CMR (162 ± 4–124 ± 4 g/m2,
p\ 0.05). There was also a significant decrease in both left
and right atrial volume as well as in right ventricular mass
index over 1 year of follow-up. Diastolic dysfunction,
graded from 0 to 4, improved from a baseline grade of 3.4
to 1.2 at 1-year follow-up.
Conclusions Long-term nocturnal hemodialysis leads to
favorable cardiovascular remodeling with a reduction in
cavity dimensions, regression of left ventricular hypertro-
phy, and an improvement in diastolic function, as assessed
by both TTE and CMR.
Keywords Home hemodialysis  High dose
hemodialysis  Left ventricular hypertrophy  Cardiac
imaging
Background
Cardiovascular disease (CVD) is the most common cause
of morbidity and mortality in patients with kidney failure
(KF) accounting for nearly half of all deaths [1]. The
prevalence of cardiac disease in chronic hemodialysis
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patients is as high as 80 % [2]. Left ventricular hypertrophy
(LVH) is an independent risk factor for cardiac death and is
present in greater than 70 % of patients at the initiation of
hemodialysis [3]. As such, many outcome studies in he-
modialysis patients use LVH as a surrogate marker for
cardiovascular events [4–7]. In addition to traditional car-
diovascular risk factors including hypertension and diabe-
tes mellitus, patients with chronic kidney disease (CKD)
exhibit non-traditional risk factors unique to the uremic
environment. These risk factors include elevated pro-
inflammatory cytokines, abnormal lipid and bone metabo-
lism, hyperparathyroidism, anemia, volume overload,
retention of uremic toxins, and sleep disorders [8–12].
The optimal frequency of hemodialysis has yet to be
determined [5]. Most often, patients undergo hemodialysis
three times per week for 4 h at a time, although this dial-
ysis dose has rarely been rigorously evaluated in prospec-
tive RCT’s. This regimen often results in complications
such as large solute and volume shifts causing unstable
blood pressures and pulmonary edema. Nocturnal home
hemodialysis (NHD) is a form of renal replacement therapy
in which hemodialysis is performed in the home for at least
6-h overnight and at least 4 days per week. NHD has not
only been shown to cost up to 20 % less than conventional
hemodialysis, but it also provides multiple clinical benefits
related to blood pressure control and mineral metabolism
[13–15].
The cardiovascular effects of NHD, as assessed by
transthoracic echocardiography (TTE) and cardiac mag-
netic resonance (CMR) imaging, have been a subject of
recent interest. Chan et al. [6] first reported an improve-
ment in left ventricular mass by TTE in an observational
study of 28 patients on NHD over a mean follow-up of
3.4 years. A subsequent randomized controlled trial of 52
patients in Alberta also demonstrated a decrease in LV
mass by CMR over a 6-month follow-up [4]. However, a
more recent study randomizing 87 patients to conventional
hemodialysis vs. NHD did not demonstrate any difference
in LV mass as assessed by CMR in NHD patients after
1 year [7]. Little is known, however, about the effects of
NHD on both atrial and ventricular remodeling as assessed
by TTE and CMR in an incident NHD population…
The primary objective of the study was to determine the
effects of NHD on cardiovascular remodeling over a one-
year follow-up using both TTE and CMR.
Methods
Study population
All patients enrolled in the NHD training program at a
single tertiary care center were asked to participate in the
study from January 2009 to December 2011 inclusive. For
inclusion into the training program, patients were required
to be able to perform NHD, have a life expectancy greater
than 12 months, and have no reliable expectation of
receiving a kidney transplant within 12 months. The study
protocol was approved by the University of Manitoba
research ethics board (REB protocol number H2008:279).
Study protocol
Upon enrollment into the NHD training program, patients
underwent 6–10 weeks of one-on-one training with a
nurse. The patients went on to perform daytime home he-
modialysis for 1–4 weeks, followed by overnight extended
hours hemodialysis. All patients had TTE and CMR studies
performed at baseline and after 1 year of NHD. All cardiac
imaging parameters were performed the day following an
overnight hemodialysis run when patients are closest to
their prescribed dry weight. Demographic, clinical, and
laboratory data were collected at baseline. Hematology and
chemistry laboratory values were obtained monthly both
pre- and post-dialysis. Parathyroid hormone and lipid
profiles were measured every 3 months.
Echocardiography
Transthoracic echocardiography was performed using a
standard echocardiography machine (GE Vivid 7, Mil-
waukee, WI, USA) at baseline and 12-month follow-up.
Cardiac chamber dimensions and function were determined
according to the American Society of Echocardiography
guidelines [16]. Transmitral left ventricular (LV) filling
velocities were measured at the tips of the mitral valve
leaflets using the apical four-chamber view and pulsed-
wave Doppler. Manual tracing of the transmitral LV filling
signal was performed to obtain peak early (E) and late
(A) transmitral velocities, E/A ratio, and E wave deceler-
ation time. Tissue Doppler-derived indices at the lateral
mitral annulus included systolic velocities (S’), early dia-
stolic velocities (E’), and late diastolic velocities (A’).
Finally the E/E’ index was determined. Echocardiographic
analysis was performed by two independent reviewers,
blinded to the clinical data, using dedicated computer
software (EchoPAC, version 110.0.0, GE Medical, Mil-
waukee, WI, USA).
Cardiac magnetic resonance imaging
All patients underwent a CMR study at baseline and at
12 months following initiation of NHD. All CMR studies
were performed using a 1.5-T Siemens Scanner (Magne-
tom Sonata, Siemens Medical Systems, Erlangen, Ger-
many). Cardiac parameters of interest included chamber
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dimensions, volumes, and systolic function which were
analyzed in accordance with guidelines of the Society for
Cardiovascular Magnetic Resonance [17]. End-systolic and
end-diastolic volumes of the left and right ventricle were
obtained using manual tracing of ventricular walls in
multiple short axis slices. End diastole was defined as the
slice in which the ventricle was at its largest volume, while
end systole was defined as the slice with the smallest
volume. Stroke volume (SV) was calculated as the differ-
ence between the end-diastolic volume (EDV) and end-
systolic volume (ESV). Left and right ventricular mass
were determined using the summation of slices method
[18]. Endocardial and epicardial borders of the left and
right ventricle, excluding papillary muscles, were manually
traced in each image slice used to calculate EDV and ESV.
Myocardial volume was calculated by multiplying these
values by slice thickness. Myocardial mass was then
determined by multiplying each volume by 1.05 g/cm3.
Analysis of CMRs was conducted by two independent
reviewers, blinded to the clinical data, using dedicated
computer software (CMR42, version 1.0.0, Circle Cardio-
vascular Imaging, Calgary, AB, Canada).
Statistical analysis
All parametric data were reported as mean ± standard
deviation (SD). Categorical data were reported as ‘‘n’’
(percentage). The Mann–Whitney U test was used to
measure the intra- and inter-observer variability for LV
end-diastolic volume and LV mass for both imaging
modalities. Statistical significance was defined as p\ 0.05.
SAS version 8.01 (SAS Institute Inc., Cary, North Caro-
lina) was used to perform the analysis.
Results
Study population
A total of 11 patients (mean age 48 ± 16 years) were
enrolled in the study, of which 6 were male (Table 1). Ten
patients underwent conventional, thrice-weekly facility-
based hemodialysis at baseline (prior to enrollment), while
one patient performed home peritoneal dialysis. The most
frequent etiology of kidney failure was glomerulonephritis
(55 %), followed by diabetic nephropathy (18 %) and
polycystic kidney disease (18 %). Cardiac comorbidities
included hypertension (63 %), ischemic heart disease
(27 %), diabetes mellitus (36 %), and valvular heart dis-
ease (9 %).
Echocardiography
The echocardiographic measurements for the study popu-
lation are listed in Table 2. There was a significant
reduction in interventricular septal (IVS) thickness (11 ± 1
to 9 ± 2 mm, p\ 0.05) as well as in posterior wall
thickness (PWT), (from 12 ± 1 to 9 ± 1 mm, p\ 0.05)
by TTE over the one-year follow-up. In addition, there was
a 15 % reduction in left ventricular mass index (LVMI,
152 ± 7 to 129 ± 8 g/m2, p\ 0.05; Fig. 1) on long-term
NHD. There were significant reductions in both left atrial
volume index (LAVI, 41 ± 5 to 34 ± 4 ml/m2, p\ 0.05)
and right atrial volume index (RAVI, 39 ± 5 to
31 ± 4 ml/m2, p\ 0.05). Finally, diastolic dysfunction
improved from a baseline grade of 3.4 to 1.2 after one-year
follow-up (p\ 0.05) as shown in Table 3. There was a
Table 1 Baseline characteristics of the NHD patient population
Characteristic Patient population
(n = 11)




Caucasian 7 (64 %)
First Nations 3 (27 %)
Asian 1 (9 %)
BMI (kg/m2), mean ± SD 23 ± 4
Prior renal transplant 4 (36 %)
Baseline dialysis modality
Hemodialysis 10 (91 %)
Peritoneal dialysis 1 (9 %)
Vascular access
AV fistula 10 (91 %)
Tunneled catheter 1 (9 %)
Cause of ESRD
Diabetic nephropathy 2 (18 %)
Glomerulonephritis 6 (55 %)
Polycystic kidney disease 2 (18 %)
Unknown 1 (9 %)
Comorbidities
Hypertension 7 (64 %)
Ischemic heart disease 3 (27 %)
Diabetes mellitus 4 (36 %)
Valvular heart disease 1 (9 %)
Smoker 1 (9 %)
Weight
Dry weight (kg) 0 months, mean ± SD 65.62 ± 14.02
Dry weight (kg) 12 months, mean ± SD 66.23 ± 14.50
Interdialytic weight gain (kg) 0 months,
mean ± SD
1.74 ± 1.18
Interdialytic weight gain (kg) 12 months,
mean ± SD
1.54 ± 0.77
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decrease in the E wave velocity with no change in the A
wave velocity over time, resulting in a decrease in the E/A
ratio over 1-year follow-up. The LV filling pressures, as
reflected by the E/E’, also improved over time. There were
no significant changes in left ventricular end-systolic and
end-diastolic dimensions, nor any change in left ventricular
Table 2 Cardiac chamber
parameters by TTE and CMR at
baseline and 1-year follow-up in
total population (n = 11)
Bold values indicate that
p\ 0.05 are significant
compared to baseline
TTE CMR
Baseline 1 year follow-
up




LVEDD (mm) 45 ± 4 46 ± 4 0.86 46 ± 1 47 ± 2 0.82
LVESD (mm) 31 ± 2 32 ± 3 0.83 31 ± 3 32 ± 3 0.71
LVEDV (mL) 96 ± 9 98 ± 10 0.85 99 ± 6 100 ± 7 0.82
LVESV (mL) 29 ± 7 30 ± 6 0.77 30 ± 5 32 ± 5 0.81
IVS (mm) 11 – 1 9 – 2 <0.05 12 – 1 9 – 1 <0.05
PWT (mm) 12 – 1 9 – 1 <0.05 12 – 1 9 – 1 <0.05
SV (mL) 63 ± 11 65 ± 7 0.68 64 ± 6 66 ± 8 0.76
HR (bpm) 70 ± 7 74 ± 9 0.62 73 ± 8 75 ± 6 0.82
CO (L/min) 4.2 ± 0.9 4.6 ± 0.7 0.54 4.4 ± 0.2 4.5 ± 0.4 0.81
LVEF (%) 69 ± 8 70 ± 5 0.76 64 ± 3 65 ± 4 0.75
LV mass index (g/m2) 152 – 7 129 – 8 <0.05 162 – 4 124 – 4 <0.05
RV parameters
RVEDD (mm) 33 ± 5 34 ± 4 0.82 34 ± 5 35 ± 3 0.76
RVEF (%) – – – 63 ± 3 64 ± 3 0.80
RV mass index (g/m2) – – – 75 – 4 62 – 3 <0.05
RV FAC (%) 45 ± 4 46 ± 5 0.76 – – –
TAPSE (mm) 3.2 ± 0.3 3.2 ± 0.4 0.91 – – –
PASP (mmHg) 32 ± 3 33 ± 4 0.72 – – –
Atrial parameters
LA diameter (mm) 32 ± 3 33 ± 4 0.72 32 ± 2 33 ± 3 0.81
LA volume index (mL/
m2)
41 – 5 34 – 4 <0.05 42 – 2 33 – 2 <0.05
RA volume index (mL/
m2)
39 – 5 31 – 4 <0.05 40 – 2 33 – 4 <0.05
Fig. 1 Cardiac dimensions by
transthoracic echocardiography
(TTE, A) and cardiac magnetic
resonance imaging (CMR, B) at
baseline and after 1 year of
nocturnal home hemodialysis
(NHD). IVS interventricular
septum, PWT posterior wall
thickness, LVMI left ventricular
mass index, RVMI right
ventricular mass index, LAVI
left atrial volume index, RAVI
right atrial volume index.
* p\ 0.05
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ejection fraction (LVEF) or cardiac output (CO) at one-
year follow-up. There was good intra-observer and inter-
observer variability for the measurement of LVMI
(Table 4).
Cardiac magnetic resonance imaging
As compared to TTE, there were similar reductions in IVS
thickness (12 ± 1–9 ± 1 mm, p\ 0.05) and PWT
(12 ± 1–9 ± 1 mm, p\ 0.05) by CMR (Table 2). There
was a significant reduction in LVMI by 23 % by CMR
(162 ± 4–124 ± 4 g/m2, p\ 0.05). In addition, there
were significant decreases in LAVI (42 ± 2–33 ± 2 ml/
m2, p\ 0.05) and RAVI (40 ± 2–33 ± 4 ml/m2,
p\ 0.05) with narrower confidence intervals using CMR
as compared to TTE (Table 2; Fig. 1). Moreover, right
ventricular mass index (RVMI) showed significant
regression after one-year follow-up (75 ± 4–62 ± 3 g/m2,
p\ 0.05). There were no significant changes in left ven-
tricular end-systolic and end-diastolic dimensions, LVEF,
nor CO at one-year follow-up using CMR. There was good
intra-observer and inter-observer variability for the mea-
surement of LVMI (Table 4).
Secondary endpoints
Data regarding blood pressure, mineral metabolism, ane-
mia and albumin levels are summarized in Table 5.
Overall, there were no significant differences in any of
these parameters after 1 year of NHD.
Discussion
Cardiovascular disease is the leading cause of death in
patients with kidney failure on dialysis. Although NHD is
associated with significant clinical benefits in this patient
population, its effects on cardiovascular remodeling remain
unclear. While previous studies have investigated the effect
of NHD on left ventricular mass alone by either TTE or
CMR, the results have been conflicting. This is the first
study to comprehensively evaluate cardiac remodeling
using both TTE and CMR in an incident cohort of patients
who have converted from conventional thrice-weekly he-
modialysis to NHD. Following one year of compliant use
of NHD, there was an improvement in biventricular mass
index, biatrial volume index, and the degree of diastolic
dysfunction in our ESRD population. Left ventricular
hypertrophy is very common in kidney failure, affecting more
than 70 % of patients at initiation of hemodialysis [3].
Table 3 Diastolic parameters by TTE at baseline and 1-year follow-
up in total population (n = 11)
Baseline 1 year follow-up p
Diastolic grade
E wave velocity (m/s) 1.4 ± 0.3 0.7 ± 0.3 \0.05
A wave velocity (m/s) 0.4 ± 0.3 0.5 ± 0.3 \0.05
E/A ratio 3.5 ± 0.2 1.4 ± 0.2 \0.05
Deceleration time (m s) 195 ± 40 208 ± 25 \0.05
Diastolic grade 3.4 1.2 \0.05
TDI parameters (LV)
Lateral S’ (cm/s) 9.8 ± 0.3 10.2 ± 0.4 0.77
Lateral E’ (cm/s) 8.2 ± 0.5 8.2 ± 0.4 0.91
Lateral A’ (cm/s) 7.9 ± 0.6 8.0 ± 0.3 0.82
Medial S’ (cm/s) 9.6 ± 0.7 9.4 ± 0.5 0.81
Medial E’ (cm/s) 8.0 ± 0.5 8.3 ± 0.6 0.83
Medial A’ (cm/s) 8.5 ± 0.4 8.1 ± 0.3 0.76
E/E’ 17 ± 1 8 ± 1 \0.05
TDI parameters (RV)
Lateral S’ 9.3 ± 0.4 9.1 ± 0.3 0.80
Lateral E’ 8.1 ± 0.3 8.0 ± 0.2 0.77
Lateral A’ 7.9 ± 0.3 7.7 ± 0.4 0.82
Data are expressed as mean ±SD
E wave early diastolic filling, A wave late diastolic filling, TDI tissue
Doppler imaging, S’ systolic myocardial velocity, E’ early diastolic
myocardial velocity, A’ late diastolic myocardial velocity
* P\ 0.05, 1-year follow-up vs. baseline
Table 4 Intra-observer and inter-observer variability for LV mass
index (n = 11)
Intra-observer Inter-observer
Absolute % Absolute %
LV mass index (g/m2)
TTE 12.2 ± 3.4 10.3 ± 4.2 11.1 ± 3.3 9.5 ± 3.9
CMR 7.6 ± 3.1 5.7 ± 1.8 8.4 ± 2.2 5.5 ± 1.4









126.5 ± 19.6 122.3 ± 18.6 0.66
Pre-dialysis DBP
(mmHg)
74.9 ± 11.9 68.6 ± 7.3 0.23
Pre-dialysis serum
calcium (mmol/L)
2.39 ± 0.22 2.42 ± 0.15 0.74
Pre-dialysis serum
phosphate (mmol/L)
1.48 ± 0.29 1.46 ± 0.38 0.87
Hemoglobin (g/L) 112 ± 11.5 113.5 ± 11.1 0.76
Albumin (g/L) 38.9 ± 1.8 38.2 ± 3.0 0.51
Parathyroid hormone 379 ± 232 249 ± 169 0.18
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In addition to traditional risk factors for the development of
LVH including hypertension, age, and valvular heart dis-
ease, there are a number of risk factors unique to patients
with chronic kidney disease (CKD). Hemodynamic
abnormalities due to volume overload, anemia, vascular
calcification, and the presence of an arterio-venous fistula
are important determinants of LV mass [19]. Additional
contributing factors include hyperphosphatemia, hyper-
parathyroidism, and hypovitaminosis D [19].
In the current study, we demonstrated significant
regression of LVH after 1 year of NHD, by both TTE and
CMR. Two previous randomized studies of NHD using
CMR alone have shown conflicting results with respect to
regression of LVH [4, 7]. While Culleton et al. [4] dem-
onstrated an 8 % reduction in LVMI by CMR after
6 months of NHD, a more recent study by Rocco et al. [7].
did not find any difference in LVMI by CMR in a larger
cohort of patients after 1 year of NHD. Our study popu-
lation was slightly younger, with a lower prevalence of
hypertension compared to these two trials. A unique find-
ing of our study was that the regression of LVH was not
associated with any improvement in blood pressure control.
This could be due to the small sample size or the low
prevalence of hypertension in our study population. It is
plausible that factors other than blood pressure play an
important role in LV remodeling in the ESRD population
on NHD.
Regression of LVH has been shown to improve sys-
tolic function, and reduce the risk of ventricular arrhyth-
mias and atrial fibrillation [20–22]. Moreover, in patients
with and without kidney failure, regression of LVH is
associated with decreased all-cause mortality, rendering
this a valid surrogate health outcome in this population
[23, 24].
Left atrial enlargement is a common echocardiographic
finding in patients with ESRD, affecting greater than 40 %
of asymptomatic patients with stage 3 to 5 CKD [25].
Multiple factors may lead to LA enlargement including
extracellular volume overload, LV dysfunction, LVH and
valvular heart disease, all of which are common in ESRD
patients [26]. Observational studies in dialysis patients
have shown that LA enlargement is significantly correlated
with mortality risk, independent of LVMI and LV ejection
fraction [26, 27]. Right atrial enlargement has also been
shown to be an independent risk factor for the development
of atrial fibrillation [28]. To our knowledge, this is the first
TTE and CMR study to report the effect of NHD on atrial
size. In our study, there was a significant decrease in RAVI
and LAVI by TTE and CMR after 1 year of NHD. These
results suggest that atrial remodeling may be reversed with
NHD, thus potentially lowering the risk of future cardio-
vascular complications, including atrial rhythm distur-
bances in the CKD population.
Diastolic dysfunction is an independent predictor of
mortality and is the most common echocardiographic
finding in asymptomatic dialysis patients [19, 29]. Dia-
stolic dysfunction is strongly associated with hypertension,
LVH, coronary artery disease, and diabetes mellitus, all of
which are common in patients with ESRD [19]. The
increase in left ventricular stiffness causes a shift of the
pressure–volume curve to the left, leading to an increased
sensitivity to changes in LV volume. Small increases in LV
volume can lead to pulmonary congestion while small
decreases in LV volume can lead to hypotension [19].
While previous studies have shown regression of LVH in
ESRD patients who convert to NHD [4, 6], no study has
reported the effect of NHD on diastolic function. This
study is the first to show a significant improvement in
diastolic dysfunction from a grade of 3.4 to 1.2 after 1 year
of NHD with an improvement in overall LV filling pres-
sures. While regression of diastolic dysfunction has been
associated with LVH regression in prior studies, it is not
known whether this leads to improved survival or a
reduction in cardiovascular events [20, 30].
There are several important limitations of our study.
First of all, due to the limited sample size, our study may
have been underpowered to detect differences in our sec-
ondary endpoints. Secondly, this was an observational
cohort study. While randomized controlled study design is
considered the gold standard, it may be difficult to ethically
justify randomizing patients to a modality of renal
replacement therapy considered by many to be inferior
either in terms of clinical parameters, costs or most likely
patient preference. Difficulty in randomizing patients to
receive home nocturnal hemodialysis versus conventional
facility-based hemodialysis in the contemporary era of
increased availability for home hemodialysis has been
reported [7]. Finally, our study reported surrogate out-
comes for cardiovascular endpoints such as morbidity and
mortality. To date, no studies have reported improvement
in cardiovascular outcomes with NHD; however, the one
study that reported cardiovascular outcomes was likely
underpowered to detect a difference [7]. An adequate study
of the effect of NHD on cardiovascular outcomes would
need to include a large number of patients over a long
follow-up period, which is logistically challenging.
Conclusions
Long-term nocturnal hemodialysis leads to favorable car-
diovascular remodeling as measured by a number of
parameters and two imaging modalities; TTE and CMR.
After 1 year of NHD, patients experience a regression of
LVH as well as an improvement in diastolic dysfunction,
atrial enlargement, and right ventricular mass index.
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